Immune checkpoint blockade (ICB) treatments, such as anti-PD1/PDL1 and anti-CTLA4 therapies, which are correlated with immune regulation, showed value in reinvigorating “exhausted” T cells and controlled tumor growth, which have succeeded in some clinical tumor treatments 126. This evidence concerns the gene CTLA4 and neoplasm.